Table 2. Trough-seated blood pressure control and response rates after 8 and 60 weeks of treatment—full analysis set in the extension period.
|
T80/A5/H12.5 |
T80/H12.5 a |
|||
|---|---|---|---|---|
| n | Achieved n (%) | n | Achieved n (%) | |
| BP control rates | ||||
| DBP <90 mm Hg at week 8 | 65 | 36 (55.4) | 61 | 16 (26.2) |
| DBP <90 mm Hg at week 60 | 43 (66.2) | 34 (55.7) | ||
| SBP <140 mm Hg at week 8 | 42 | 23 (54.8) | 34 | 11 (32.4) |
| SBP <140 mm Hg at week 60 | 27 (64.3) | 26 (76.5) | ||
| BP response rates | ||||
| DBP <90 mm Hg or ⩾10 mm Hg decrease from baseline at week 8 | 65 | 42 (64.6) | 61 | 18 (29.5) |
| DBP <90 mm Hg or ⩾10 mm Hg decrease from baseline at week 60 | 48 (73.8) | 40 (65.6) | ||
| SBP <140 mm Hg or ⩾20 mm Hg decrease from baseline at week 8 | 42 | 26 (61.9) | 34 | 11 (32.4) |
| SBP <140 mm Hg or ⩾20 mm Hg decrease from baseline at week 60 | 30 (71.4) | 26 (76.5) | ||
| DBP/SBP <90/140 mm Hg rates | ||||
| SBP <140 mm Hg and DBP <90 mm Hg at week 8 | 65 | 30 (46.2) | 61 | 13 (21.3) |
| SBP <140 mm Hg and DBP <90 mm Hg at week 60 | 41 (63.1) | 33 (54.1) | ||
Abbreviations: A5, amlodipine 5 mg; BP, blood pressure; DBP, diastolic blood pressure; H12.5, hydrochlorothiazide 12.5 mg; SBP, systolic blood pressure; T80, telmisartan 80 mg.
Values are presented as n (%).
T80/A5/H12.5, patients who took T80/A5/H12.5 in the double-blind treatment period and in the extension period (weeks 8 and 60).
T80/H12.5, patients who took T80/H12.5 in the double-blind treatment period (week 8) and T80/A5/H12.5 in the extension period (week 60).
a
Patients who took T80/H12.5 in the double-blind treatment period (week 8) and T80/A5/H12.5 in the extension period (week 60).